Robin P F Dullaart1, Eke G Gruppen2, Geesje M Dallinga-Thie3. 1. Department of Endocrinology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands. Electronic address: r.p.f.dullaart@int.umcg.nl. 2. Department of Endocrinology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
OBJECTIVES: High density lipoprotein (HDL)-associated paraoxonase-1 (PON-1) exerts anti-oxidative properties, whereas phospholipid transfer protein (PLTP) is able to convert mature HDL into larger and smaller HDL particles. Here we tested associations of PON-1 with PLTP in type 2 diabetes mellitus (T2DM), a condition characterized by lower PON-1 activity and higher PLTP activity. DESIGN AND METHODS: Serum PON-1 (arylesterase activity), plasma PLTP activity (liposome-vesicle HDL system), and (apo)lipoproteins were measured in 81 T2DM subjects (mean age 59±9years; 31 women; no insulin treatment). In 48 participants, HDL subfractions were measured by nuclear magnetic resonance spectroscopy. RESULTS: In univariate correlation analysis, PON-1 activity was positively related to PLTP activity (r=0.348, p=0.001). PLTP activity was positively related to blood pressure, body mass index and triglycerides, whereas PON-1 activity was positively to HDL cholesterol and apoA-I (p<0.05 to <0.01 for each). Both PLTP activity and PON-I activity were positively related to large HDL particles (r=0.379, p=0.008 and r=0.411, p=0.004, respectively). In multivariable linear regression analysis, PON-1 activity was associated with PLTP activity independent of clinical covariates and HDL cholesterol or apoA-I (β=0.340, p=0.001 and β=0.320, p=0.003, respectively). The association of PON-1 activity with PLTP activity was lost in analysis which included large HDL particles (large HDL: β=0.411, p=0.004). CONCLUSIONS: PON-1 activity is positively related to PLTP activity in T2DM, raising the possibility that PLTP could act to maintain PON-1. This association may in part be attributable to a common relationship of PON-1 and PLTP with large HDL particles.
OBJECTIVES: High density lipoprotein (HDL)-associated paraoxonase-1 (PON-1) exerts anti-oxidative properties, whereas phospholipid transfer protein (PLTP) is able to convert mature HDL into larger and smaller HDL particles. Here we tested associations of PON-1 with PLTP in type 2 diabetes mellitus (T2DM), a condition characterized by lower PON-1 activity and higher PLTP activity. DESIGN AND METHODS: Serum PON-1 (arylesterase activity), plasma PLTP activity (liposome-vesicle HDL system), and (apo)lipoproteins were measured in 81 T2DM subjects (mean age 59±9years; 31 women; no insulin treatment). In 48 participants, HDL subfractions were measured by nuclear magnetic resonance spectroscopy. RESULTS: In univariate correlation analysis, PON-1 activity was positively related to PLTP activity (r=0.348, p=0.001). PLTP activity was positively related to blood pressure, body mass index and triglycerides, whereas PON-1 activity was positively to HDL cholesterol and apoA-I (p<0.05 to <0.01 for each). Both PLTP activity and PON-I activity were positively related to large HDL particles (r=0.379, p=0.008 and r=0.411, p=0.004, respectively). In multivariable linear regression analysis, PON-1 activity was associated with PLTP activity independent of clinical covariates and HDL cholesterol or apoA-I (β=0.340, p=0.001 and β=0.320, p=0.003, respectively). The association of PON-1 activity with PLTP activity was lost in analysis which included large HDL particles (large HDL: β=0.411, p=0.004). CONCLUSIONS:PON-1 activity is positively related to PLTP activity in T2DM, raising the possibility that PLTP could act to maintain PON-1. This association may in part be attributable to a common relationship of PON-1 and PLTP with large HDL particles.
Keywords:
High density lipoprotein subfractions; High density lipoproteins; Paraoxonase-1 activity; Phospholipid transfer protein activity; Type 2 diabetes mellitus
Authors: Htet W Khine; John F Teiber; Robert W Haley; Amit Khera; Colby R Ayers; Anand Rohatgi Journal: Atherosclerosis Date: 2017-06-03 Impact factor: 5.162
Authors: Sara Sokooti; Jose L Flores-Guerrero; Lyanne M Kieneker; Hiddo J L Heerspink; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Sara Sokooti; Tamas Szili-Torok; Jose L Flores-Guerrero; Maryse C J Osté; António W Gomes-Neto; Jenny E Kootstra-Ros; Hiddo J L Heerspink; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart Journal: Biomolecules Date: 2020-03-21